Related Experiment Video
Updated: Aug 14, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Emerging Options for the Prevention and Management of Clostridioides difficile Infection
Anne J Gonzales-Luna1, Travis J Carlson2, Kevin W Garey3
1Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4849 Calhoun Road, Houston, TX, 77204, USA.
Abstract:
Agents in development for the prevention or treatment of Clostridioides difficile infection can be split into three broad categories: antibiotics, microbiome restoration, and vaccines. Given the extensive list of agents currently in development, this narrative review will focus on agents that have progressed into late-stage clinical trials, defined as having a Phase III clinical trial registered on ClinicalTrials.gov. These agents include one antibiotic (ridinilazole), three live biotherapeutic products (LBPs) (CP101, RBX2660, and SER109), and two toxoid vaccines (PF06425090 and a second toxoid vaccine). As new prevention and treatment strategies enter the market, clinicians and administrators will need knowledge of these products to make rational decisions on how best to adopt them into clinical practice.
Insights
New Clostridioides difficile infection treatments in late-stage trials include antibiotics, microbiome restoration, and vaccines. This review covers agents in Phase III trials for effective clinical adoption.
Area of Science:
- Infectious Diseases
- Microbiology
- Vaccinology
Background:
- Clostridioides difficile infection (CDI) poses a significant clinical challenge.
- Existing treatments have limitations, driving the need for novel strategies.
- A diverse range of therapeutic approaches are under investigation for CDI.
Approach:
- This narrative review focuses on agents in late-stage clinical development (Phase III).
- Key agents examined include one antibiotic, three live biotherapeutic products (LBPs), and two toxoid vaccines.
- Information was gathered from registered clinical trials on ClinicalTrials.gov.
Key Points:
- Ridinilazole is a novel antibiotic targeting CDI.
- CP101, RBX2660, and SER109 represent LBPs for microbiome restoration.
- PF06425090 and another toxoid vaccine are in late-stage development for CDI prevention/treatment.
Conclusions:
- Several promising agents are progressing through Phase III trials for CDI.
- Understanding these late-stage candidates is crucial for clinical decision-making.
- The review provides insights into emerging CDI prevention and treatment strategies.
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:

